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Abstract 
Review on ORAI3, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: TMEM142C 
HGNC (Hugo): ORAI3 
Location: 16p11.2 
Note 
ORAI3 is a member of the ORAI family proteins 
discovered in 2006 as the essential pore-forming 
components of the low-conductance, highly Ca2+-
selective CRAC channels whose activation is 
dependent on depletion of the endoplasmic 
reticulum Ca2+ stores (Feske et al., 2006; Vig et al., 
2006; Zhang et al., 2006).  
In Greek mythology, the ORAI are the keepers of 
the gates of heaven: Eunomia (Order or Harmony), 
Dike (Justice) and Eirene (Peace). 
DNA/RNA 
Description 
ORAI3 is encoded by the gene TMEM142C 
(HUGO Gene Nomenclature Committee).  
The ORAI3 gene is located on chromosome 16 in 
the p11.2. 
Transcription 
Size of ORAI3 transcript: 2.2 kb; NCBI ORAI3 
mRNA model: NM_152288.  
All three ORAI isoforms are widely expressed at 
the mRNA level and can be incorporated into the 
plasma membrane when ectopically expressed. 
Broad expression of ORAI3 transcripts has been 
shown by Northern blot analysis: ORAI3 transcripts 
are expressed in heart, brain, kidney, thymus, lung, 
spleen, skeletal muscle, small intestine, as well as 
in primary aortic endothelial cells and bone marrow 
derived mast cells (Gwack et al., 2007). ORAI3 
appears to be the only family member that is 
strongly expressed at the RNA level in brain. 
(ORAI2 transcripts are prominent in kidney, lung, 
and spleen (Gwack et al., 2007)). 
Transcripts expression  
In immune cells, transcripts taken from isolated 
primary CD3+/CD4+ cells (Th-lymphocytes), 
CD3+/CD8+ cells (Tc-lymphocytes), CD19+ cells 
(B-lymphocytes) and BMMC showed that ORAI3 
expression is readily detectable in Th-, Tc-, and B- 
lymphocytes and BMMC (Gross et al., 2007).  
mRNA expression in normal tissues has been 
assessed by different techniques (microarrays, 
RNAseq, SAGE). Microarrays analyses show that 
ORAI3 is overexpressed in prostate, lung, 
monocytes and whole blood 
(http://biogps.org/#goto=genereportid=93129, with 
overexpression defined as 3 times the mean 
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expression observed in the 83 tissues or cells tested 
in this study). ORAI3 mRNA expression is least 
important in pancreas, brain (especially the 
occipital lobe) and T cells (CD4+ as well as CD8+). 
Protein 
Description 
Description of the protein sequence. 
Molecular weight: 31499 Da. 
Sequence length: 295 amino acids. 
ORAI3 is a plasma membrane protein containing 
four transmembrane domains with intracellular N- 
and C-termini. ORAI3 contains a binding domain 
for calmodulin in its N-terminus, and a coiled-coil 
domain for protein interaction in its C-terminus. 
Examination of the overall protein sequence of 
ORAI3 reveals high percentage of homology with 
the family members: 63.2% with ORAI1 and 66.4% 
with ORAI2 (60.3% between ORAI1 and ORAI2). 
These homology percentages increase when the 
comparison concerns the transmembrane domains: 
93.8% with both ORAI1 and ORAI2, (92.5% 
between ORAI1 and ORAI2) (Feske et al., 2006; 
Hewavitharana et al., 2007). The pore-forming 
transmembrane domains of all three ORAI proteins 
show a high degree (~82%) of conservation. 
The amino acid sequence of ORAI3 shows marked 
differences from its isoforms, particularly in the 
regions outside of the essential pore-forming 
domains, which might explain its unique properties 
and the differences with other isoforms in the 
modes of regulation and modulation from its 
isoforms (Shuttleworth, 2012). 
The sequence identities between ORAI3 and 
ORAI1 in the cytosolic N- and C-termini are 34% 
and 46%, respectively, and is 21% in the 
extracellular loop between transmembrane domains 
3 and 4 (Shuttleworth, 2012). 
The N-terminus of ORAI3 comprises ~65 amino 
acids and has no clusters of prolines and arginines 
seen in ORAI1 (N-terminus domain containing ~90 
amino acids and rich in clusters of prolines and 
arginines) (Takahashi et al., 2007; Frischauf et al., 
2008). ORAI3 has a second extracellular loop 
linking transmembrane domains 3 and 4 which is 
longer than that of ORAI1 and ORAI2 (~72 amino 
acids in ORAI3 compared to only 38 amino acids in 
ORAI1). ORAI3 has a cluster of 22 positively 
charged amino acid residues immediately prior to 
the first transmembrane region which is fully 
conserved among all three ORAI channels (H44-
R66 in ORAI3 and H69-R91 in ORAI1), and has 
three conserved glutamates located at the C-
terminus to which is attributed the fast Ca2+-
dependent inactivation of ORAI3 (Lee et al., 2009). 
The ORAI3 N-terminus appears critical for 
switching a store-operated channel to an 
exclusively arachidonate regulated channel 
(Thompson et al., 2010). 
The residues E81 and E165 in the transmembrane 
domains 1 and 3, and E85, D87 and E89 in the 
extracellular 1-2 loop are critical determinants of a 
high Ca2+ selectivity. Other studies using a 
cysteine-scanning mutagenesis approach in ORAI3 
revealed that Ca2+ selectivity was exclusively 
determined by the E81 residue alone (McNally et 
al., 2009). 
Replacing the N-terminal cytosolic domain of 
ORAI3 with the corresponding domain of ORAI1 
doubles the magnitude of the measured store-
operated Ca2+ currents, whilst the reverse exchange 
virtually eliminates all currents. N-terminal deletion 
experiments narrow the critical region essential for 
the activation of ORAI3 to amino acids 42-62 (Lis 
et al., 2010). The appearance of significant store-
operated currents dependes on a single specific 
lysine residue K60 in ORAI3, the conservation of 
this residue in ORAI1 and ORAI3 cannot explain 
the differences in the magnitude of store-operated 
Ca2+ currents between these two ORAI family 
members. N-terminal deletions of residues between 
W51 and Y55 significantly increase store-operated 
ORAI3-dependent currents (Bergsmann et al., 
2011). The only sequence difference between 
ORAI1 and ORAI3 in this region is the substitution 
of a lysine in ORAI1 for an arginine at position 53 
in ORAI3. 
 
Schematic representation of ORAI protein structure and organization. Domains of human ORAI1, 2 and 3. P: proline-rich 
region, R: arginin-rich region, R/K: arginine-lysine-rich region, TM: transmembrane domain, CC: coiled-coil domain (Derler et al., 
2012). 
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ORAI3 protein sequence of amino acids. ORAI3 protein (1 .. 295) has four helical transmembrane domains: T1 (63 .. 82) (20 
amino acids), T2 (95 .. 115) (21 amino acids), T3 (157 .. 177) (21 amino acids), T4 (244 .. 264) (21 amino acids). 
 
 
ORAI3 lacks C195, a reactive cysteine present in 
ORAI1 that serve as a detection system primarily 
for changes in the extracellular oxidative 
environment, and contains two additional cysteines 
within the extracellular loop between TM3 and 
TM4. The absence of C195 in ORAI3 makes it 
resistant to H2O2-inactivation, since pre-incubation 
with H2O2of ORAI1/STIM1 expressing cells (HEK; 
T cells) inhibits activation of ORAI1, but not of 
ORAI3, and reinsertion of C195 within ORAI3 
renders ORAI3 channels redox sensitive (Bogeski 
et al., 2010). 
Post-translational modifications of the protein 
Glycosylation: 
Unlike ORAI1, ORAI3 does not have a 
glycosylation site on the asparagine residue (N223) 
situated between the transmembrane domains TM3 
et TM4 (Frischauf et al., 2008; Prakriya et al., 
2006). 
ORAI1 has a putative N-glycosylation motif (NVS) 
in its extracellular loop between predicted 
transmembrane segments 3 and 4. This motif is 
absent in ORAI2 and 3 (Gwack et al., 2007). 
ORAI3 migration properties do not change by 
tunicamycin treatment. Indeed, HEK293 cells 
stably transfected with FLAG-tagged ORAI and 
treated with 2µg/ml tunicamycin, showed that 
ORAI3 migrated at positions close to their 
predicted molecular masse (32.5 kDa). 
Phosphorylation: 
Since ORAI3 is a tetraspanning plasma membrane 
protein, it contains three intracellular regions that 
can potentially be phosphorylated by intracellular 
protein kinases: the N-terminus, an intracellular 
loop between transmembrane domains 2 and 3, and 
the C-terminus, each intracellular region potentially 
contains one or more phosphorylation sites. Ser-27 
and Ser-30 have been identified as the main 
phosphorylation sites in ORAI1 within its N-
terminus. They are conserved throughout evolution 
in all mammalian ORAI1 proteins. Mutations at 
these phosphorylation sites increase store-operated 
Ca2+ entry (SOCE) and CRAC current suggesting 
that ORAI1 phosphorylation at these residues by 
protein kinase C (PKC) suppresses SOCE and 
CRAC channel activation. However, Ser-27 and 
Ser-30 are not present in ORAI2 and ORAI3. 
A phosphorylation of ORAI3 peptide has been 
revealed by a phosphoproteome analysis of human 
liver cells (Sui et al., 2008). This phosphorylation 
site is located in the C-terminus of ORAI3 on a 
tyrosine residue (Y278). Experimental ORAI3 
phosphorylation has also been demonstrated in 
HEK293 cells (Kawasaki et al., 2010). 
To examine in vivo PKC-mediated 
phosphorylation, HEK293 cells expressing FLAG-
tagged ORAI were incubated with 32P monosodium 
phosphate, and then stimulated with thapsigargin in 
the presence of extracellular Ca2+. Thapsigargin 
mobilizes Ca2+ from the ER and the extracellular 
space and activates Ca2+/DAG-dependent PKC 
isoforms. ORAI1 phosphorylation is enhanced in 
response to thapsigargin. The levels of ORAI3 
phosphorylation have been less than half of that 
observed for ORAI1 (Kawasaki et al., 2010). 
Other phosphorylation sites on ORAI3 were 
predicted by NetPhos2.0: 13 serine sites (S20, S45, 
S50, S57, S64, S65, S68, S86, S191, S203, S213, 
S214 and S20), 3 threonine sites (T26, T183 and 
T190) and 2 tyrosine sites (Y146 and Y278). 
Expression 
ORAI3 is only expressed in mammals (Cai, 2007). 
ORAI3 seems to be ubiquitously expressed in 
human 
(http://www.proteinatlas.org/ENSG00000175938/ti
ssue), and mouse, showing a minor presence in 
skeletal muscle, spleen and colon (Cordeiro and 
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Strauss, 2011; Gao et al., 2010; Gross et al., 2007). 
More specifically, ORAI3 expression has been 
reported in brain, heart, kidney, testis, intestine, 
placenta, lung (Gwack et al., 2007; Motiani et al., 
2013a), vascular smooth muscle cells (Trebak, 
2012), airway smooth muscle in human (Peel et al., 
2008) and macrophages. ORAI3 mRNA is usually 
much less expressed compared to ORAI1 in cells of 
lymphoid origin. ORAI1, ORAI2, and ORAI3 are 
expressed at similar levels in rat microglia (Hoth 
and Niemeyer, 2013). 
Localisation 
ORAI3 localizes to the plasma membrane and 
functions as a Ca2+-selective ion channel (Feske et 
al., 2006; Vig et al., 2006; Zhang et al., 2006; 
Prakriya et al., 2006). This has been confirmed by 
immunocytochemistry of tagged proteins expressed 
in Jurkat T cells and in HEK293 cells. All three 
ORAI isoforms are expressed and localized at or 
near the plasma membrane, with little or no overlap 
with the ER marker ERP72. This localization was 
not grossly altered after store depletion with 
thapsigargin (Gwack et al., 2007). During meiosis, 
ORAI proteins get internalized into intracellular 
vesicles and store-operated currents are suppressed 
(Yu et al., 2009). 
Function 
In SOC channels: 
ORAI3 presents a single putative channel pore and 
has a role as a store-operated Ca2+ (SOC) channel. 
SOC channels are the major route for Ca2+ entry in 
non-excitable cells, and they include ORAI 
channels characterized by high selectivity for Ca2+ 
over monovalent cations, low single-channel 
conductance (<1 pS), and an inwardly rectifying 
current-voltage (I-V) relationship. Functional 
CRAC/SOC channels are formed by a tetrameric 
assembly of ORAI1/2/3 subunits (Ji et al., 2008; 
Mignen et al., 2008a; Penna et al., 2008; Maruyama 
et al., 2009). 
ORAI3 is different from its family members, 
notably because of its exclusive presence in 
mammals (Cai, 2007) and its receptivity to 
pharmacological modulation (Schindl et al., 2008). 
All three isoforms are selective to Ca2+, ORAI3 
being more permeant to monovalent cations such as 
Na+ (DeHaven et al., 2007). Indeed, the ORAI3 
currents display a significantly increased 
permeability to Na+ when measured in the absence 
of external divalent cations (Lis et al., 2007). 
ORAI3 expression is capable of inducing a store-
induced conductance, but its magnitude is 
considerably smaller than that seen with ORAI1. 
In HEK293 cells, human SCID T cells and 
fibroblasts, in which store depletion has been 
induced with thapsigargin, ORAI1 was shown to be 
the major regulator of store-operated Ca2+ influx, 
whereas ORAI3 can complement partially (partly 
compensate in the absence of functional ORAI1) 
and ORAI2 has a lesser role (Gwack et al., 2007). 
Combined overexpression of ORAI3 and STIM1 
results in substantial reconstitution of Ca2+ entry in 
SCID fibroblasts (Gwack et al., 2007). ORAI3 
expression also rescues normal store-operated Ca2+ 
entry in cells in which such entry was reduced by 
knockdown of ORAI1 (Mercer et al., 2006; 
DeHaven et al., 2007). 
ORAI1, ORAI2, and ORAI3 channels are all 
similarly inhibited by extracellular Ca2+, indicating 
similar affinities for Ca2+ within the selectivity 
filter. ORAI3 channels seem to differ from ORAI1 
and ORAI2 in being somewhat resistant to the 
process of Ca2+ depotentiation (DeHaven et al., 
2007). Moreover, like ORAI1, ORAI3 can 
potentiate store-operated Ca2+ entry in HEK293 
cells expressing TRPC6 or TRPC3 (Liao et al., 
2007). 
ORAI3 and ORAI1 channels participate in store-
operated Ca2+ influx in human airway smooth 
muscle cells (Peel et al., 2008). Cells transfected 
with siRNA against ORAI3 display abnormal 
(cyclopiazonic acid) CPA-mediated Ca2+ signals. 
Both Ca2+ release from the stores and Ca2+ influx 
are reduced in the ORAI3 knockdown cells, 
suggesting that cells with reduced ORAI3 
expression have a lower Ca2+ store content and that 
ORAI3 plays a role in regulating basal Ca2+ levels 
or in Ca2+ release from the stores (Peel et al., 2008). 
In addition, ORAI genes expression and CRAC 
activation has also reported in the human retinal 
pigment epithelium (Potier et al., 2009; Darbellay 
et al., 2009; Bisaillon et al., 2010). 
ORAI3 upregulation contributes to vascular smooth 
muscle remodeling and neointimal hyperplasia 
caused by vascular injury. 
ORAI3 has been shown to be an important 
component of store-independent arachidonate-
regulated Ca2+ (ARC) entry in HEK293 cells 
(Mignen and Shuttleworth, 2000), and more 
recently of a store-independent leukotriene C4-
regulated Ca2+ (LRC) entry pathway in vascular 
smooth muscle cells (Zhang et al., 2013). 
In ARC channels: 
ORAI3 has been identified as an essential 
component of the store-independent, arachidonic 
acid activated, Ca2+-selective ARC channels 
(Mignen and Shuttleworth, 2000; Mignen et al., 
2008b). These channels are found in a variety of 
different cell types, frequently co-existing with 
store-operated CRAC channels (Mignen et al., 
2003; Mignen et al., 2005; Li et al., 2008; Yeung-
Yam-Wah et al., 2010), and sharing similar basic 
biophysical properties. They are pentameric 
aggregates consisting of three ORAI1 and two 
ORAI3 subunits that form a functional ARC 
channel pore (Mignen et al., 2008b; Mignen et al., 
ORAI3 (ORAI calcium release-activated calcium modulator 3) Hasna J, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(3) 180 
2007; Thompson et al., 2010). Two ORAI3 
subunits are required within the pentamer to make 
the ARC channel sensitive to activation by low 
concentrations of arachidonic acid. ARC channels 
are characterized by being activated by low 
concentrations (2-8 µM) of arachidonic acid, 
insensitive to 2-APB, and with an absolutely 
dependence on the pool of STIM1 residing in the 
plasma membrane for their activation (Mignen et 
al., 2009). The acquisition of selective activation by 
arachidonic acid depends on the cytosolic N-
terminal domain of ORAI3 (Thompson et al., 
2010). 
The ARC currents are distinguished from the co-
existing CRAC channel currents by their store-
independent activation, and the absence of any 
detectible fast inactivation. Expression of a 
dominant-negative mutant of ORAI3 (E81Q) had 
no effect on store-operated CRAC channel currents, 
but reduced currents through the store-independent 
ARC channels to negligible levels (Mignen et al., 
2008b). 
A recent study indicates a role of ARC channels in 
insulin secretion by pancreatic β cells (Yeung-Yam-
Wah et al., 2010). It has been shown that the known 
ability of glucose and various insulin stimulants 
including acetylcholine and cholecystokinin to 
induce increases in cellular arachidonic acid results 
in activation of ARC channels in the β cells, 
increasing cytosolic Ca2+ levels and enhancing the 
subsequent insulin secretion (Yeung-Yam-Wah et 
al., 2010). 
In LRC channels: 
ORAI3 channels are also implicated in store-
independent, leukotriene C4 (LTC4)-regulated Ca2+ 
(LRC) channels. Comparison of AA (arachidonic 
acid)- and LTC4-activated currents in vascular 
smooth muscle cells and in HEK293 cells using 
whole-cell and perforated patch-clamp recording 
shows indistinguishable non-additive LTC4- and 
AA-activated currents that both require ORAI1 and 
ORAI3. This suggests that ARC and LRC 
conductances are mediated by the same channel. 
Experiments using a non-metabolizable form of AA 
or an inhibitor of 5-lipooxygenase suggest that 
ARC and LRC currents in both cell types can be 
activated by either LTC4 or AA, with LTC4 being 
more potent. Although the plasma membrane (PM)-
STIM1 was required for current activation by LTC4 
and AA under whole-cell patch-clamp recordings in 
both cell types, ER-STIM1 was sufficient with 
perforated patch recordings. These results 
demonstrate that ARC and LRC currents are 
mediated by the same cellular populations of 
STIM1, ORAI1, and ORAI3 (Zhang et al., 2013). 
In summary, ORAI3 proteins contribute to Ca2+ 
entry into cells through both store-dependent, Ca2+ 
release-activated Ca2+ (CRAC) channels and store-
independent, arachidonic acid (AA)-regulated Ca2+ 
(ARC) and leukotriene C4 (LTC4)-regulated 
Ca2+(LRC) channels (ORAI1/3 heteromultimers). 
ORAI3 activation and interaction with STIM 
proteins 
ORAI channels are activated by STIM1 or STIM2, 
single-pass transmembrane proteins localized 
predominantly in the membrane of the endoplasmic 
reticulum. STIM proteins have a long C-terminal 
cytoplasmic region and contain an N-terminal EF-
hand located in the ER lumen that functions as a 
sensor of ER Ca2+ levels (Roos et al., 2005; Liou et 
al., 2005; Williams et al., 2001; Stathopulos et al., 
2006). 
The activation of ORAI channels by STIM depends 
on Ca2+ store depletion and is reversible once the 
stores are refilled (Luik et al., 2008; Soboloff et al., 
2006). STIM1 activates store-operated Ca2+ 
channels only when it is not fixing Ca2+, e.g. when 
the stores are depleted (Zhang et al., 2005). One 
minute after store depletion, STIM proteins are 
redistributed in puncta in close proximity to the 
plasma membrane (Liou et al., 2005; Luik et al., 
2008; Várnai et al., 2007; Baba et al., 2006), where 
they co-localize with and activate ORAI channels, 
allowing Ca2+ influx (Liou et al., 2005; Wu et al., 
2006; Muik et al., 2008). This process implies 
tetramerisation of STIM1 proteins using the N-
terminus (Luik et al., 2008). It is thought that within 
these puncta, STIM1 communicates with and opens 
CRAC channels located to the plasma membrane 
(Luik et al., 2006; Parvez et al., 2008). 
The initial interaction of STIM1 with the ORAI 
channels involves their cytosolic C-terminal region 
(Li et al., 2007; Muik et al., 2008; Frischauf et al., 
2009). In all three ORAI subtypes, this region 
contains a predicted coiled-coil domain that is 
critical for interactions with STIM1 (Muik et al., 
2008). 
Truncation analysis identified a cytoplasmic region 
of STIM1, termed the CRAC activation domain 
(CAD)/STIM1 ORAI1 activating region (SOAR) to 
be sufficient to activate ORAI1 (Kawasaki et al., 
2009; Muik et al., 2009; Park et al., 2009; Yuan et 
al., 2009). The cytoplasmic N and C termini of 
ORAI1 mediate channel opening by interaction 
with STIM1. 
The activation of ORAI3-induced store-operated 
currents is significantly slower than that seen with 
ORAI1 and ORAI2 (Lis et al., 2007). Contrary to 
ORAI1, both ORAI2 and ORAI3 exhibit a 15-17 
fold higher coiled-coil probability (Frischauf et al., 
2009). A single point mutation in the ORAI1 
coiled-coil domain (L273S) abrogates 
communication with STIM1 C-terminus (Frischauf 
et al., 2009; Muik et al., 2008). A single point 
mutation (L285S) within ORAI3 coiled-coil 
domain results in a partial inhibition of the 
interaction with STIM1 and subsequent activation 
of ORAI3 currents. Full inhibition of the ORAI3-
ORAI3 (ORAI calcium release-activated calcium modulator 3) Hasna J, et al. 
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induced currents requires incorporation of an 
additional mutation (L292S) in the coiled-coil 
domain. 
According to Bergsmann, activation of ORAI 
channels requires coupling of the C terminus of 
STIM to the N and C termini of ORAI (Bergsmann 
et al., 2011), since increasing N-terminal 
truncations causes a progressive decrease of ORAI3 
fast inactivation concomitant with diminished 
binding to calmodulin.  
Therefore, a fully conserved N-terminal ORAI 
region (aa 48-65 in ORAI3) is essential for STIM1-
dependent STIMulation (Derler et al., 2009; Li et 
al., 2007; Yuan et al., 2009; Fahrner et al., 2009; 
Park et al., 2009; Lis et al., 2010).  
Moreover, a single lysine within this conserved 
region (K60E in ORAI3) represents a critical 
residue for store-operated activation (Lis et al., 
2010). 
Interaction between ORAI family members 
ORAI3 can multimerize with ORAI1 to form cation 
channels that conduct Ca2+to some degree, since 
HEK293 cells stably expressing FLAG-tagged 
ORAI2 and ORAI3 revealed co-
immunoprecipitation of ORAI2 and ORAI3 with 
transiently overexpressed Myc-ORAI1. Thus, 
ORAI members form homomultimers and can also 
form heteromultimers (Gwack et al., 2007). 
Protein Interactions other than STIM 
In addition to STIM1, p45 renamed as CRACR2A 
(CRAC regulator 2A) is also shown to co-
immunoprecipitate with ORAI1, ORAI2 and 
ORAI3, suggesting a conserved binding mechanism 
with all the ORAI proteins, and that the ORAI 
channels, STIM1 and CRACR2A may form a 
ternary complex though direct interaction. 
Various other proteins and lipids have been 
identified to interact with either STIM1 or ORAI3 
or both. Among them is calmodulin (Mullins et al., 
2009; Parvez et al., 2008; Bergsmann et al., 2011). 
Calmodulin binds to ORAI3 and, together with 
STIM, contributes to fast calcium-dependent 
inactivation; the structural studies show that 
CRACR2A/B is also able to interact with ORAI3 
(Srikanth et al., 2010) but to date there is no 
evidence of functional regulation, because ORAI3 
is able to form some complex with STIM-1 (Faouzi 
et al., 2011).  
All proteins that interact with STIM1 are able to 
modulate ORAI3 function indirectly. Thus, SARAF 
(Palty et al., 2012), MS4A4B (Howie et al., 2009), 
Golli (Walsh et al., 2010), adenylyl cyclase type 8 
(AC8) (Martin et al., 2009), the polycystin-1 
cleavage product P100 (Woodward et al., 2010), 
caveolin (Yu et al., 2010), SPCA2 (Feng et al., 
2010) and the L-type Ca2+channel (Cav1.2) (Wang 
et al., 2010) or the phospholipids PIP2 and PIP3 
(Korzeniowski et al., 2009; Walsh et al., 2009) are 
able to modulate indirectly ORAI3 activity. 
ORAI3 inactivation 
Fast inactivation of ORAI channels is mediated by 
cooperative interplay of several structures within 
ORAI proteins, by the CRAC modulatory domain 
(CMD) of STIM1, and via calmodulin binding to 
the ORAI N terminus (Parekh and Putney, 2005; 
Lee et al., 2009; Frischauf et al., 2011; Derler et al., 
2009). 
ORAI3 currents exhibit a marked fast inactivation 
within the first 100 ms, while that of ORAI2 or 
ORAI1 show less robust feedback regulation (Lis et 
al., 2007; Schindl et al., 2009; Lee et al., 2009). 
This effect depends on the presence of three 
conserved glutamates (E281, E283, E284) in the C-
terminal region of ORAI3 (Lee et al., 2009). 
According to Yamashita et al. (2007), fast 
inactivation is determined by the same acidic 
residues involved in determining Ca2+ selectivity. A 
STIM1 C-terminus domain that include an acidic 
cluster (amino acids 475-483) termed CRAC 
Modulatory Domain (CMD) is also indispensable 
for fast ORAI channel inactivation (Derler et al., 
2009; Mullins et al., 2009; Lee et al., 2009), since 
mutations in the CMD results in ORAI3 currents 
with attenuated or even abolished Ca2+-dependent 
inactivation (Derler et al., 2009; Lee et al., 2009). 
On the other hand, Litjens et al. (2004) suggest that 
fast inactivation may be calmodulin (CaM) 
dependent and involves a region in the cytosolic N-
terminal domain of ORAI3 (S45-K62) that binds 
CaM in a Ca2+-dependent manner (Mullins et al., 
2009; Frischauf et al., 2011). Transient CaM 
binding is assumed to mediate fast inactivation. The 
process may be that CaM transiently competes with 
STIM1 for the N-terminal interaction site on ORAI 
essential for channel gating. 
Not only the C- but also the N-terminus and the 
second intracellular loop between TM2 and TM3 
contribute to ORAI inactivation/gating in a 
cooperative manner (Frischauf et al., 2011) and 
modulate fast and slow inactivation as revealed by 
chimeric and mutational approaches (Srikanth et al., 
2010). ORAI fast inactivation also involves the 
pore region since mutations of negatively charged 
residues within the pore of ORAI results in 
attenuation of Ca2+-dependent inactivation 
(Yamashita et al., 2007). 
Pharmacology 
To date there is no specific inhibitor of ORAI3 but 
ORAI3 channels can be blocked by generic 
blockers of calcium entry channels such as La3+ 
(50-100 µM) and Gd3+ (1-5 µM). Other non-
specific blockers include SKF96365, the myosin 
light chain kinase inhibitor ML-9 (Smyth et al., 
2008), and the bistrifluoromethyl-pyrazole 
derivative BTP2 (Zitt et al., 2004) can be used. 
Another compound extensively studied is 2-
aminoethoxydiphenyl borate (2-APB), originally 
characterized as an inhibitor of InsP3 receptors 
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(Maruyama et al., 1997; Bilmen and Michelangeli, 
2002), later shown to have multiple diverse effects 
including both the inhibition and activation of 
various different members of the TRP channel 
family (Voets et al., 2001; Trebak et al., 2002; 
Chung et al., 2004; Hu et al., 2004; Li et al., 2006; 
Juvin et al., 2007), and the inhibition of SERCA 
pumps (Missiaen et al., 2001; Peppiatt et al., 2003), 
as well as to affect store-operated Ca2+ entry via 
CRAC channels (Gregory et al., 2001; Iwasaki et 
al., 2001; Prakriya and Lewis, 2001). 
2-APB displays a bi-functional effect that is 
dependent on the concentration used. High 
concentrations of 2-APB were shown to increase 
store-operated currents in cells expressing STIM1 
and ORAI3 (Lis et al., 2007; DeHaven et al., 2008; 
Peinelt et al., 2008; Schindl et al., 2008), 
accompanied by marked changes in ion selectivity 
by increasing ORAI3 channel pore size from ~3.8 
Å to more than 5.34 Å, an effect that was 
apparently dependent on the E165 residue of 
ORAI3 that lies in the third transmembrane domain 
(Schindl et al., 2008). The residues that assist in 
formation of the 2-APB-activated ORAI3 pore are 
lined by TM1 residues, but also allows for TM3 
E165 to approach the central axis of the channel 
that forms the conducting pathway, or pore 
(Amcheslavsky et al., 2014). Transmembrane 
domains 2 and 3, together with the linking 
intracellular loop, are required for 2-APB to 
directly activate ORAI3 channels (Zhang et al., 
2008). 
ORAI3 can be directly activated by high 
concentrations of 2-APB, in a STIM1- and store 
depletion-independent manner (DeHaven et al., 
2008; Peinelt et al., 2008; Schindl et al., 2008; 
Zhang et al., 2008; Wang et al., 2009). These direct 
2-APB induced currents display large inward and 
outward currents (i.e. they show double 
rectification) and a leftward shift in the reversal 
potential, features that indicate a marked reduction 
in Ca2+ selectivity, and an increased permeability to 
monovalent cations (DeHaven et al., 2008; Peinelt 
et al., 2008; Schindl et al., 2008; Zhang et al., 
2008). 
When ORAI3 forms a store operated channel, store-
operated ORAI3 currents are potentiated by 2-APB 
at low concentrations (<10 µM) without affecting 
ion selectivity (Yamashita et al., 2011). This effect 
requires the presence of STIM1, and is strictly 
dependent on store depletion. 
The most obvious unique property of the channels 
involving ORAI3 is their ability to be activated 
independently of store depletion, either 
pharmacologically by 2-APB or, physiologically, 
by agonist-generated increased levels of 
intracellular arachidonic acid. 
A recent study by (Zeng et al., 2014) shows that the 
ryanodine receptor (RyR) agonist 4-chloro-3-
ethylphenol (4-CEP) blocks ORAI1/3 store-
operated channels. 4-CEP induces a significant Ca2+ 
release in rat L6 myoblasts, but inhibits SOCE. The 
inhibitory effect is concentration-dependent and 
more potent than the one of its analogues 4-CmC 
and 4-chlorophenol (4-ClP). In the HEK293 T-REx 
cells overexpressing STIM1/ORAI1-3, 4-CEP 
inhibited the ORAI1, ORAI2 and ORAI3 currents 
evoked by thapsigargin. The 2-APB-induced 
ORAI3 current was also blocked by 4-CEP. This 
inhibitory effect was reversible and independent of 
the Ca2+ release. The two analogues, 4-CmC and 4-
ClP, also inhibited the ORAI1-3 channels. Excised 
patch and intracellular application of 4-CEP 
demonstrated that the action site was located 
extracellularly (Zeng et al., 2014). 
GSK-7975A and GSK-5503A are selective CRAC 
channel blockers that inhibit both ORAI1 and 
ORAI3 currents by acting downstream of STIM1 
oligomerization and STIM1/ORAI1 interaction, 
potentially via an allosteric effect on the selectivity 
filter of ORAI (Derler et al., 2012). Both GSK 
compounds fully inhibited ORAI3 currents. 
Similarly, Synta-66 inhibited ORAI3 currents at a 
similar rate as the GSK compounds. By contrast, 10 
µM La3+ blocked ORAI3 currents more rapidly. 
The GSK compounds appeared to inhibit ORAI3 
currents slightly faster than those of ORAI1. 
Overall these GSK compounds were equally 
effective at blocking ORAI1 and ORAI3, and 
inhibition occurred at a substantially slower rate 
than La3+. Inhibition of ORAI currents by GSK 
compounds is not readily reversible: neither ORAI1 
nor ORAI3 currents showed substantial recovery 
from block by GSK-7975A or GSK-5503A over a 
4-5 min wash-out period. 
2-APB stimulated ORAI3 currents are less 
susceptible to GSK-7975A. 10 µM GSK-7975A 
was totally ineffective in inhibiting these ORAI3 
currents in contrast to those activated via STIM1. 
50 µM GSK-7975A caused 50% inhibition and 100 
µM GSK-7975A caused full inhibition. The GSK 
CRAC channel blockers did not differentiate 
between ORAI1 and ORAI3 channels consistent 
with the conserved pore geometry and selectivity 
filter among the ORAI isoforms. 
Homology 
ORAI3 (encoding gene: MGC13024 located on 
chromosome 16) has two human homologs: ORAI1 
(FLJ14466, chromosome 12) and ORAI2 (C7orf19, 
chromosome 7) (Feske et al., 2006). ORAI3 made 
an evolutionary appearance in mammals, evolving 
from ORAI1 rather than ORAI2 (Cai, 2007) and 
manifesting conductances that display unique 
features in their gating, selectivity, regulation and 
mode of activation (Shuttleworth, 2012). 
ORAI3 is the 'newest' ORAI family member in the 
evolutionary tree (Shuttleworth, 2012). Orthologous 
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ORAI3 genes are found in the following species: 
chimpanzee (98.98% homology), dog (92.20% 
homology), cow (90.51% homology), rat (89.83% 
homology), mice (88.48% homology). 
Mutations 
Note 
Understanding of the role of ORAI1, and indeed its 
initial identification, came from the study of 
patients carrying functionally critical mutations in 
this gene. To date, no equivalent identification of 
patients bearing similar mutations in ORAI3 have 
been identified. (Diseases associated to absence of 
ORAI2, ORAI3 or STIM2 function have not been 
identified in human yet). 
Implicated in 
Note 
ORAI3 overexpression is associated with breast, 
lung, leukemia and prostate cancers. 
Breast cancer 
Note 
ORAI3 channels are reported to be highly 
expressed in breast cancer (BC) tissues and breast 
cancer cell lines MCF-7 and T47D compared to 
adjacent non cancerous tissues and non cancerous 
cell lines, respectively (Faouzi et al., 2011). They 
are also shown to be involved in proliferation, cell 
cycle progression and survival of BC cells by 
regulating the G1 phase and G1/S transition 
regulatory proteins. Thus, ORAI3 knockdown by 
specific siRNA inhibits cell proliferation, arrests 
cell cycle progression in G1 phase, and increases 
apoptosis in these cells (Faouzi et al., 2011). This 
phenotype is associated with a reduction in CDK4 
and CDK2 (cyclin-dependent kinases) and cyclin E 
and cyclin D1 expression, an accumulation of 
p21Waf1/Cip1 (a cyclin-dependent kinase 
inhibitor) and p53 (a tumor-suppressor protein) 
together with an increase of Bax/Bcl-2 ratio. 
Interestingly, these effects seem to be specific to 
cancer cells, since down-regulation of ORAI3 
channels does not affect either cell proliferation or 
cell survival of normal breast cells. Annexin V and 
7-AAD double staining and analysis of the anti-
apoptotic protein Bcl-2 to the pro-apoptotic protein 
Bax ratio revealed that the induced cell mortality by 
ORAI3 knockdown was mainly apoptotic as 
demonstrated by the increased percentage of 
Annexin V-positive cells and the increased 
Bax/Bcl-2. 
The same study showed that ORAI3 contributes to 
Ca2+ influx in BC cells where both Store Operated 
Calcium Entry (SOCE) amplitude and resting 
[Ca2+]i decreased significantly with ORAI3 
knockdown. The authors concluded that the ORAI3 
involvement in cell proliferation/survival and cell 
cycle progression may be at least partially linked to 
the calcium influx through the channels since the 
reduction of external calcium concentration [Ca2+]o 
to 0.2 mM decreases significantly BC cell 
proliferation (Faouzi et al., 2011). 
A subsequent study highlighted a correlation 
between ORAI3 and the oncogene c-myc 
expression in tumor tissues and in BC cell lines: 
ORAI3 and c-myc were over-expressed in 70% and 
80% cases respectively. Expression of c-myc, as 
assessed by RT-qPCR, is higher in the MCF-7 
cancer cell line than in the non-cancerous MCF-
10A cell line. A similar over-expression pattern was 
shown for ORAI3 in these cell lines (Faouzi et al., 
2013). ORAI3 down-regulation reduces both c-myc 
expression and activity levels exclusively in BC 
cells, whereas ORAI1 (one of the two mammalian 
homologs to ORAI3) induced an upregulation of c-
myc mRNA. The involvement of c-myc in the 
ORAI3 signaling was demonstrated when silencing 
c-myc resulted in closely-similar and non-additive 
effects to the ones induced by ORAI3 
downregulation: decreased cell proliferation, cell 
cycle arrest with a significant accumulation of the 
cells in the G0/G1 phase, increased cell mortality 
(Faouzi et al., 2013).  
Authors showed that ORAI3 channels affect c-myc, 
most likely via the MAP Kinase pathway, as 
demonstrated by decreased phosphorylation levels 
of extracellular signal-regulated kinases 1 and 2 
(ERK1/ERK2) after ORAI3 downregulation 
(Faouzi et al., 2013).  
Parallel studies also reported that ORAI3 mediates 
SOCE in estrogen-receptor-positive (ER+) BC cell 
lines (Motiani et al., 2010), whereas in estrogen-
receptor-negative (ER-) BC cell lines, SOCE is 
mediated by ORAI1. This study was the first to 
describe SOCE and endogenous calcium release-
activated currents (CRAC) that are mediated by 
native ORAI3 channels and highlights a potential 
connection between estrogen receptor alpha (ERα) 
and ORAI3 (Motiani et al., 2010). Authors then 
reported that knockdown of ERα decreases ORAI3 
expression level leading to a decrease in ORAI3-
mediated SOCE and CRAC current, while 
activation of ERα increased ORAI3 expression and 
SOCE in MCF7 cells (Motiani et al., 2013b). 
Consistently with the above cited studies, ORAI3 
knockdown inhibits SOCE-dependent 
phosphorylation of both ERK1/2 and focal adhesion 
kinase (FAK).  
It also decreases the transcriptional activity of 
nuclear factor of activated T-cells (NFAT), which 
was associated with decreased cell growth and 
Matrigel invasion of ER+ MCF7 cells in contrast to 
ER- MDA-MB231 cells where no effects were 
observed (Motiani et al., 2013b). 
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Lung cancer 
Note 
An overexpression of ORAI3 was observed in 
66.7% of human tumor samples as compared to the 
human non-tumoral samples (40/60) as revealed by 
immunohistochemistry. The 60 lung 
adenocarcinomas were classified according to 
grading system proposed by Yoshizawa et al. 2011 
(low, intermediate and high grades). The ORAI3 
staining score is reported to be highly expressed in 
higher tumor grade (high grade; n= 16) as 
compared to low tumor grades (Ay et al., 2013).  
ORAI3 is also expressed in non small cell lung 
carcinoma cells (NSCLCC) such as NCI-H23, NCI-
H460, A549 and Calu-1. In NCI-H23 and NCI-
H460 cells, ORAI3 is a major actor of Store 
Operated Calcium Entry (Ay et al., 2013). Ay et al. 
(2013) demonstrated that ORAI3 is involved in 
NSCLCC proliferation. Indeed, ORAI3 inhibition 
induces a strong decrease in NSCLCC proliferation, 
accumulating cells in G0/G1 phase of the cell cycle. 
This accumulation in G0/G1 phase is associated 
with a decrease in Cyclin D1/cdk4 and Cyclin 
E/cdk2 proteins level. No effect is observed on 
apoptosis. The same study demonstrated that SOCE 
induces Akt phosphorylation in NSCLCC and 
ORAI3 inhibition decreases this activation 
demonstrating ORAI3 can promote proliferation 
through SOCE by activating Akt pathway. They 
also showed that neither ORAI1 nor ORAI2 are 
involved in SOCE in NSCLC cell lines, suggesting 
that ORAI3 is the main component of SOCE in 
those cells (Ay et al., 2013). 
The same type of mechanism is observed with 
TRPC1 in NSCLCC. Indeed Tajeddine and Gailly 
(2012) have demonstrated that TRPC1 is involved 
in G1/S transition in A549 NSCLC cell line through 
SOCE. They showed that cell cycle arrest after 
TRPC1 inhibition induces a decrease in EGFR 
activation and subsequent signaling (PI3K/Akt, 
MAPK).  
Those two studies suggest that SOCE is an 
important mechanism in proliferation of NSCLCC. 
Indeed, EGFR signaling is overactivated in 
NSCLCC either by constitutive activation of EGFR 
or K-Ras mutation. ORAI3, able to activate this 
pathway, hence can be a potential target for anti-
cancer drug. 
Myeloid leukemia 
Note 
The mRNA levels of ORAI3 in both human 
leukemia and human myeloma tipifarnib-sensitive 
cell lines were significantly higher than in the 
tipifarnib-insensitive human myeloma cells. 
Tipifarnib is a new apoptotic agent that inhibits 
farnesyltransferase responsible for the transfer of a 
farnesyl group to Ras protein. Tipifarnib activates 
ORAI3-mediated SOC leading to [Ca2+]i increase. 
Moreover, ORAI3 functional expression was higher 
in 2-APB-sensitive leukemia and myeloid cells as 
compared to 2-APB-insensitive myeloid cells 
(Yanamadra et al., 2011). These results suggest that 
Tipifarnib-resistant cells express less ORAI3 
ORAI3 conferring protection against apoptotic 
effect of Tipifarnib (Yanamadra et al., 2011). 
Prostate cancer 
Note 
ORAI3 mRNA expression levels are significantly 
reduced in tumours when compared to non-tumour 
tissues from 13 prostate cancer patients. mRNA 
expression levels of ORAI3 are decreased in both 
androgen-sensitive human prostate adenocarcinoma 
cell line (LNCaP) and androgen-insensitive prostate 
cancer cell line (DU145), when compared to human 
prostate epithelial cells from healthy tissue. The 
pharmacological effects of 2-APB on CRAC 
channels in prostate cancer cells differ from those 
in human prostate epithelial cells, and siRNA based 
knock-down experiments indicate changed ORAI3 
channel levels are underlying the altered 
pharmacological profile (Holzmann et al., 2013). 
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